[go: up one dir, main page]

MA29816B1 - Composes de benzimidazole thiophene - Google Patents

Composes de benzimidazole thiophene

Info

Publication number
MA29816B1
MA29816B1 MA30794A MA30794A MA29816B1 MA 29816 B1 MA29816 B1 MA 29816B1 MA 30794 A MA30794 A MA 30794A MA 30794 A MA30794 A MA 30794A MA 29816 B1 MA29816 B1 MA 29816B1
Authority
MA
Morocco
Prior art keywords
thiophene compounds
compounds
benzimidazole thiophene
benzimidazole
preparing
Prior art date
Application number
MA30794A
Other languages
English (en)
Inventor
Mui Cheung
Kyle Allen Emmitte
James Michael Salovich
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of MA29816B1 publication Critical patent/MA29816B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'INVENTION CONCERNE DES COMPOSÉS DE BENZIMIDAZOLE THIOPHÈNE, DES COMPOSITIONS PHARMACEUTIQUES CONTENANT LESDITS COMPOSÉS, DES PROCÉDÉS PERMETTANT DE PRÉPARER LESDITS COMPOSÉS ET L'UTILISATION LESDITS COMPOSÉS EN TANT QU'AGENTS PHARMACEUTIQUES.
MA30794A 2005-09-06 2008-03-31 Composes de benzimidazole thiophene MA29816B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71433705P 2005-09-06 2005-09-06
US78624406P 2006-03-27 2006-03-27

Publications (1)

Publication Number Publication Date
MA29816B1 true MA29816B1 (fr) 2008-09-01

Family

ID=37631488

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30794A MA29816B1 (fr) 2005-09-06 2008-03-31 Composes de benzimidazole thiophene

Country Status (28)

Country Link
US (2) US7595330B2 (fr)
EP (1) EP1937671B1 (fr)
JP (1) JP5002597B2 (fr)
KR (1) KR20080047585A (fr)
AR (1) AR055616A1 (fr)
AT (1) ATE452132T1 (fr)
AU (1) AU2006287766B2 (fr)
BR (1) BRPI0615668A2 (fr)
CA (1) CA2621879A1 (fr)
CR (1) CR9786A (fr)
CY (1) CY1109916T1 (fr)
DE (1) DE602006011192D1 (fr)
DK (1) DK1937671T3 (fr)
EA (1) EA014111B1 (fr)
ES (1) ES2337929T3 (fr)
HR (1) HRP20100122T1 (fr)
IL (1) IL189897A0 (fr)
JO (1) JO2578B1 (fr)
MA (1) MA29816B1 (fr)
MX (1) MX2008003173A (fr)
NO (1) NO20081160L (fr)
NZ (1) NZ566345A (fr)
PE (1) PE20070518A1 (fr)
PL (1) PL1937671T3 (fr)
PT (1) PT1937671E (fr)
SI (1) SI1937671T1 (fr)
TW (1) TW200800967A (fr)
WO (1) WO2007030361A2 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101495474A (zh) * 2006-05-23 2009-07-29 沃泰克斯药物股份有限公司 可用作蛋白激酶抑制剂的噻吩-甲酰胺类
US7615643B2 (en) 2006-06-02 2009-11-10 Smithkline Beecham Corporation Benzimidazole thiophene compounds
WO2007143506A2 (fr) * 2006-06-02 2007-12-13 Smithkline Beecham Corporation Composés d'éther benzylique de benzimidazole thiophène substitué non cyclique
JP2009539770A (ja) * 2006-06-02 2009-11-19 スミスクライン ビーチャム コーポレーション Ｐｌｋに対する活性を有するベンゾイミダゾール置換チオフェン誘導体
JPWO2008087736A1 (ja) * 2007-01-19 2010-05-06 宇部興産株式会社 アラルキルオキシ又はヘテロアラルキルオキシ基を有する芳香族アミンの製法
JP2010531887A (ja) * 2007-06-26 2010-09-30 グラクソスミスクライン エルエルシー ベンズイミダゾールチオフェンの調製方法
US8273890B2 (en) * 2007-06-29 2012-09-25 4Sc Ag Thiophene-imidazopyridines
EP2100894A1 (fr) 2008-03-12 2009-09-16 4Sc Ag Pyridopyrimidinones utilisés comme inhibiteurs de la kinase de type Plk1 (polo-like kinase)
WO2009151914A1 (fr) * 2008-05-27 2009-12-17 Smithkline Beecham Corporation Procédés de traitement de néoplasmes au moyen d'une combinaison d'un inhibiteur de plk et d'un rétinoïde
WO2009154645A1 (fr) * 2008-06-20 2009-12-23 Smithkline Beecham Corporation Méthodes permettant de traiter des tumeurs du système nerveux central
CA2745596A1 (fr) * 2008-12-18 2010-10-28 F. Hoffmann-La Roche Ag Thiazolyl-benzimidazoles
WO2011049625A1 (fr) 2009-10-20 2011-04-28 Mansour Samadpour Procédé de criblage d'aflatoxine dans des produits
HUE035059T2 (hu) 2009-11-05 2018-05-02 Rhizen Pharmaceuticals S A Új benzopirán-kinát modulátorok
ES2710874T3 (es) 2011-05-04 2019-04-29 Rhizen Pharmaceuticals S A Compuestos novedosos como moduladores de proteína cinasas
SMT201900334T1 (it) 2012-07-04 2019-07-11 Rhizen Pharmaceuticals S A Inibitori selettivi di pi3k delta
KR102574152B1 (ko) * 2020-03-27 2023-09-05 (주) 업테라 Plk1의 선택적 분해를 유도하는 벤즈이미다졸 티오펜 유도체 화합물
KR102337029B1 (ko) 2020-03-27 2021-12-09 (주) 업테라 Plk1 선택적 분해 유도 화합물
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025080946A2 (fr) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Inhibiteurs de ras
WO2025171296A1 (fr) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Inhibiteurs de ras
WO2025240847A1 (fr) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Inhibiteurs de ras
WO2025255438A1 (fr) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Procédés de traitement d'une maladie ou d'un trouble lié à la protéine ras
WO2025265060A1 (fr) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Compositions thérapeutiques et procédés de gestion d'effets liés au traitement
WO2026006747A1 (fr) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026015801A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble liés à ras
WO2026015796A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026015825A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Utilisation d'un inhibiteur de ras pour traiter le cancer du pancréas
WO2026015790A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990146A (en) * 1997-08-20 1999-11-23 Warner-Lambert Company Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation
US6162804A (en) * 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
AU760020B2 (en) 1998-08-31 2003-05-08 Merck & Co., Inc. Novel angiogenesis inhibitors
BR0313160A (pt) * 2002-08-08 2005-07-12 Smithkline Beecham Corp Composto, composição farmacêutica, métodos para tratar uma condição e um neoplasmo suscetìvel em um animal em um animal, processo para preparar um composto e uso de um composto
AU2003903440A0 (en) * 2003-07-04 2003-07-17 James Hardie International Finance B.V. Rainscreen apparatus and method
US7465807B2 (en) * 2003-10-16 2008-12-16 Smithkline Beecham Corporation Process for preparing benzimidazole thiophenes
JP4721428B2 (ja) 2003-10-20 2011-07-13 日本精工株式会社 ステアリング装置
GB0402809D0 (en) 2004-02-09 2004-03-10 Glaxo Group Ltd Chemical compounds
JP2009507022A (ja) * 2005-09-06 2009-02-19 スミスクライン ビーチャム コーポレーション ベンズイミダゾールチオフェン類の位置選択的調製方法
WO2007030359A1 (fr) * 2005-09-06 2007-03-15 Smithkline Beecham Corporation Composés de thiophène de benzimidazole comme modulateurs plk
EP2474546A1 (fr) 2006-01-23 2012-07-11 Vertex Pharmaceuticals Inc. Tiophène-carboxamides utiles en tant qu'inhibiteurs de kinases de protéine
WO2007143506A2 (fr) * 2006-06-02 2007-12-13 Smithkline Beecham Corporation Composés d'éther benzylique de benzimidazole thiophène substitué non cyclique
JP2009539770A (ja) * 2006-06-02 2009-11-19 スミスクライン ビーチャム コーポレーション Ｐｌｋに対する活性を有するベンゾイミダゾール置換チオフェン誘導体

Also Published As

Publication number Publication date
SI1937671T1 (sl) 2010-04-30
NZ566345A (en) 2010-04-30
PT1937671E (pt) 2010-03-12
CY1109916T1 (el) 2014-09-10
AU2006287766A1 (en) 2007-03-15
AR055616A1 (es) 2007-08-29
EA014111B1 (ru) 2010-10-29
EP1937671A2 (fr) 2008-07-02
US7595330B2 (en) 2009-09-29
PE20070518A1 (es) 2007-06-12
KR20080047585A (ko) 2008-05-29
PL1937671T3 (pl) 2010-05-31
JP5002597B2 (ja) 2012-08-15
MX2008003173A (es) 2008-03-18
JP2009508816A (ja) 2009-03-05
CR9786A (es) 2008-05-22
EA200800546A1 (ru) 2008-08-29
ES2337929T3 (es) 2010-04-30
NO20081160L (no) 2008-05-29
TW200800967A (en) 2008-01-01
AU2006287766B2 (en) 2010-06-24
US20070270437A1 (en) 2007-11-22
WO2007030361A3 (fr) 2007-05-31
US7786127B2 (en) 2010-08-31
JO2578B1 (en) 2011-02-27
IL189897A0 (en) 2008-08-07
BRPI0615668A2 (pt) 2011-05-24
HK1117504A1 (en) 2009-01-16
EP1937671B1 (fr) 2009-12-16
CA2621879A1 (fr) 2007-03-15
ATE452132T1 (de) 2010-01-15
DK1937671T3 (da) 2010-04-26
US20080214567A1 (en) 2008-09-04
WO2007030361A2 (fr) 2007-03-15
DE602006011192D1 (de) 2010-01-28
HRP20100122T1 (hr) 2010-05-31

Similar Documents

Publication Publication Date Title
MA29816B1 (fr) Composes de benzimidazole thiophene
JO3408B1 (ar) مركبات بترين سلفون اميد ثيازول و أوكسازول
MA31606B1 (fr) Anticorps anti-cd 79b immunoconjugues et procedes d'utilisation
MA30042B1 (fr) Composes calcilytiques
MA30765B1 (fr) Derives innovants du thiophene
MA31502B1 (fr) Anticorps anti-notch 1 specifiques a nrr et ses procedes d'utilisation
MX2009005462A (es) Analogos de 7,8-saturados-4,5-epoxi-morfinano.
MA31605B1 (fr) Anticorps anti-cd79b humanisés, immunoconjugués, et procédés d'utilisation
ATE526318T1 (de) Farnesoid-x-rezeptor-agonisten
WO2007077561A3 (fr) Compositions et procédés permettant d'améliorer le captage in-vivo d'agents pharmaceutiques
MA31907B1 (fr) Nouveaux herbicides
ATE469895T1 (de) Cgrp-rezeptorantagonisten
MXPA05007328A (es) Composiciones que contienen agentes antiacne y el uso de las mismas.
EP2382201A4 (fr) Composés plasmalogènes, compositions pharmaceutiques contenant ceux-ci et procédés pour traiter les maladies liées au vieillissement
WO2009071689A3 (fr) Dérivés d'oxindole substitués par halogène en position 5 et leur utilisation pour traiter des maladies liées à la vasopressine
MA30331B1 (fr) ANTICORPS à EFGL 7 ET LEURS PROCEDES D'UTILISATION
EP2217063A4 (fr) Paclitaxels thiolés destinés à réagir avec des nanoparticules d'or, servant d'agents de distribution de médicaments
ATE459620T1 (de) Benzimidazolthiophenverbindungen als plk- modulatoren
MA39163B1 (fr) Forme cristalline de (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone et utilisation de celle-ci en tant qu'antagonistes des recepteurs de l'orexine
EP2285215A4 (fr) Nouveaux composés, compositions pharmaceutiques contenant ceux-ci, et procédés d'utilisation de ceux-ci
WO2008070354A3 (fr) Benzidimidazole thiophènes substitués en 5 et 6 pour plk
EP2020223A3 (fr) Produit de soin capillaire ayant une teneur en diamants
MX2007013327A (es) Formulaciones de liberacion prolongada.
UA87903C2 (en) Herbicidal composition
NL1029686A1 (nl) Oxazolidinonen die oxindolen bevatten als antibacteriele middelen.